期刊
JOURNAL OF LIPID RESEARCH
卷 52, 期 4, 页码 679-687出版社
ELSEVIER
DOI: 10.1194/jlr.M013664
关键词
cholesterol/metabolism; drug therapy; gene expression
资金
- Merck Research Laboratories
Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks cholesterol absorption. Both elevate serum PCSK9 protein levels in patients, which could attenuate their efficacy by reducing the amount of cholesterol cleared from circulation. To determine whether PCSK9 inhibition could enhance LDL-c lowering of both statins and ezetimibe, we utilized small interfering RNAs (siRNAs) to knock down Pcsk9, together with ezetimibe, rosuvastatin, and an ezetimibe/rosuvastatin combination in a mouse model with a human-like lipid profile. We found that ezetimibe, rosuvastatin, and ezetimibe/rosuvastatin combined lower serum cholesterol but induce the expression of Pcsk9 as well as the Srebp-2 hepatic cholesterol biosynthesis pathway. Pcsk9 knockdown in combination with either treatment led to greater reductions in serum non-HDL with a near-uniform reduction of all LDL-c subfractions. In addition to reducing serum cholesterol, the combined rosuvastatin/ezetimibe/Pcsk9 siRNA treatment exhibited a significant reduction in serum APOB protein and triglyceride levels.jlr Taken together, these data provide evidence that PCSK9 inhibitors, in combination with current therapies, have the potential to achieve greater reductions in both serum cholesterol and triglycerides.-Ason, B., S. Tep, H. R. Davis, Jr., Y. Xu, G. Tetzloff, B. Galinski, F. Soriano, N. Dubinina, L. Zhu, A. Stefanni, K. K. Wong, M. Tadin-Strapps, S. R. Bartz, B. Hubbard, M. Ranalletta, A. B. Sachs, W. M. Flanagan, A. Strack, and N. A. Kuklin. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J. Lipid Res. 2011. 52: 679-687.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据